Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetesPRNewsWire • 09/17/25
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?Zacks Investment Research • 09/17/25
Data on Eli Lilly's Weight Loss Pill Hasn't Thrilled Investors. New Updates Are Complicating the Picture.Barrons • 09/17/25
Lilly says its experimental GLP-1 pill better than Novo's Rybelsus in diabetes studyReuters • 09/17/25
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trialCNBC • 09/17/25
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trialPRNewsWire • 09/17/25
Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategyReuters • 09/17/25
Prospect of daily weight loss pill moves closer after Lily trial successProactive Investors • 09/17/25
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffsWSJ • 09/17/25
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of MedicinePRNewsWire • 09/16/25